1Prentice HG, Caillot D, Dupont B, et al. Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients: meeting report. Acta Haematol, 1999, 101: 56-62.
2Kapsi SG, Ayres JW. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. Int J Pharm, 2001, 229: 193-203.
3Barone JA , Moskovitz BL, Guarnieri J, et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy, 1998, 18: 295-301.
4Reynes J, Bazin C, Ajana F,et al. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob Agents Chemother, 1997, 41: 2554-2558.
5Groll AH, Wood L,Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother, 2002,46: 2554-2563.
6Michallet M, Persat F, Kranzhofer N, et al. Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Bone Marrow Transplant, 1998, 21: 1239-1243.
7Prentice AG, Warnock DW, Johnson SA, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother, 1994, 34: 247-252.
8de Repentigny L, Ratelle J, Leclerc JM, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother,1998,42: 404-408.
9Zhou H, Goldman M, Wu J, et al. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol, 1998, 38: 593-602.
10Zhao Q, Zhou H, Pesco-Koplowitz L. Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection. J Clin Pharmacol, 2001, 41: 1319-1328.
4McGinnis MR. Medical mycology in the next century. Jpn J Med Mycol, 1998,39:1- 9.
5Iwen PC, Hinrichs SH, Rupp ME. Utilization of the internal transcribed spacer regions as molecular targets to detect and identify human fungal pathogens. Med Mycol, 2002,40:87- 109.
6Calderone R, Suzuki S, Cannon R, et al. Candida albicans: adherence, signaling and virulence. Med Mycol, 2000,38: (Suppl 1): 125- 137.
7Reiss E, Obayashi T, Orle K, et al. Non- culture based diagnostic tests for mycotic infections. Med Mycol, 2000,38(Suppl 1): 147- 159.
8Verweij PE, Figueroa J, Van Burik J, et al. Clinical applications of non- culture based methods for the diagnosis and management of opportunistic and endemic mycoses. Med Mycol, 2000,38(Suppl 1): 161- 171.
2Montillo M, Mirto S, Petti MC, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia [J]. American Journal of Hematology, 1998,58(2):105-109.
3Lee WL, Yuan CC, Chao HT, et al. Vaginal obliteration after total body irradiation and chemotherapy as treatment for acute myeloid leukemia [J]. European Journal of Obstetrics, Gynecology & Reproductive Biology, 2000,90(1):77-79.
4Mattiuzzi GN, Estey E, Raad I, et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infaetions during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome[J].Cancer, 2003,97(2):450-456.
5Auner HW, Sill H, Mulabecirovic A, et al.Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma[J]. Annals of Hematology, 2002,81(7):374-377.
6Talemoto K,Yamanoto Y,Ueda Y, et al. Comparative studies on the efficacy of ambisome and fungizone in a mouse model of disseminated aspergiIlosis [J]. J Animicrob Chemther, 2004,53 (2):311-317.
